Cardiovascular events: A class effect by COX-2 inhibitors;Eventos cardiovasculares: Um efeito de classe dos inibidores de COX-2

Arquivos Brasileiros de Cardiologia

Volumn 85, Issue 3, 2005, Pages 222-229

  Fernandes Araujo, Leila ^a   De Matos Soeiro, Alexandre ^a   De Lara Fernandes, Juliano ^a   Serrano Jr , Carlos Vicente ^a,b  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b NONE   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC; ETORICOXIB; IBUPROFEN; LUMIRACOXIB; NABUMETONE; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; PROSTACYCLIN; PROSTAGLANDIN E2; ROFECOXIB; THROMBOXANE A2; VALDECOXIB;

ANTIINFLAMMATORY ACTIVITY; CANCER PREVENTION; CARDIOVASCULAR EFFECT; COLON ADENOMA; FOOD AND DRUG ADMINISTRATION; HUMAN; MUSCULOSKELETAL DISEASE; OSTEOARTHRITIS; OUTCOMES RESEARCH; REVIEW; RHEUMATOID ARTHRITIS; STOMACH PROTECTION;

EID: 25144453881     PISSN: 0066782X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (45)

1. Nussmeier NA, Whelton AA, Brown MT. Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery. N Engl J Med 2005; 352: 1081-91.
2. FitzGerald GA, Patrono CP. The coxibs, selective inhibitors of cycloxygenase-2. N Engl J Med 2001; 345: 433-42.
3. Dieppe PA, Ebrahim S, Martin RM, Jüni P. Lessons from the withdrawal of rofecoxib. Br Med J 2004; 329: 867-8.
4. Mukherjee D, Nissen SE, Topol EJ. Risk of cardiovascular events associated with selective COX-2 inhibitors. JAMA 2001; 286: 954-9.
5. Silverstein FE, Faich G, Goldstein JL et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial. JAMA 2000; 284: 1247-55.
6. Rang HP, Dale MM, Ritter JM. Farmacologia. 4a edição. Rio de Janeiro: Guanabara Koogan, 2001.
7. FitzGerald GA. Cardiovascular pharmacology of nonselective nonsteroidal anti-inflammatory drugs and coxibs: clinical considerations. Am J Cardiol 2002; 89: 26D-32D.
8. Bombardier C, Laine L, Reicin A et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med 2000; 343: 1520-8.
9. Bakhle YS, Botting RM. Cyclooxygenase-2 and its regulation in inflammation. Mediators Inflamm 1996; 5: 305-23.
10. Seibert K, Zhang Y, Leahy K et al. Pharmacological and biochemical demonstration of the role of cyclooxygenase-2 in inflammation and pain. Proc Natl Acad Sci USA 1994; 91: 12013-17.
11. Sano H, Hla T, Maier JA et al. In vivo cyclooxygenase expression in synovial tissues of patients with rheumatoid arthritis and osteoarthritis and rats with adjuvant and streptococcal cell wall arthritis. J Clin Invest 1992; 89: 97-108.
12. Fosslein E. Adverse effects of nonsteroidal anti-inflammatory drugs on the gastrointestinal system. Ann Clin Lab Sci 1998; 28: 67-81.
13. Bresalier RS, Sandler RS, Quan H et al. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 2005; 352: 1092-102.
14. Solomon SD, McMurray JJV, Pfeffer MA et al. Cardiovascular risks associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 2005; 352: 1071-80.
15. FitzGerald GA. Coxibs and cardiovascular disease. N Engl J Med 2004; 351: 1709-11.
16. Topol EJ. Failing the public health-rofecoxib, Merk, and the FDA. N Engl J Med 2004; 351: 1707-09.
17. Drazen JM. COX-2 inhibitors: a lesson in unexpected problems. N Engl J Med 2005; 352: 1131-32.
18. Psaty BM, Furberg CD. COX-2 inhibitors - lessons in drug safety. N Engl J Med 2005; 352: 1133-35.
19. Topper JN, Cai J, Falb D, Gimbrone MA Jr. Identification of vascular endothelial genes differentially responsive to fluid mechanical stimuli: cycloxygenase-2, manganese superoxide dismutase, and endothelial cell nitric oxide synthase are selectively up-regulated by steady laminar shear stress. Proc Natl Acad Sci U S A 1996; 93: 10417-22.
20. Narumiya S, FitzGerald GA. Genetic and pharmacological analysis of prostanoid receptor function. J Clin Invest 2001; 108: 25-30.
21. Murata T, Ushikubi F, Matsuoka T et al. Altered pain perception and inflammatory response in mice lacking prostacyclin receptor. Nature 1997; 388: 678-82.
22. Solomon DH, Glynn RJ, Levin R, Avorn J. Nonsteroidal anti-inflammatory drug use and acute myocardial infarction. Arch Intern Med. 2002; 162(10): 1099-1104.
23. Capone ML, Tacconelli S, Sciulli MG et al. Clinical pharmacology of platelet, monocyte, and vascular cycloxigenase inhibition by naproxen and low-dose aspirin in healthy subjects. Circulation 2004; 109: 1468-71.
24. Van Hecken A, Schwartz JI, Depre M et al. Comparative inhibitory activity of rofecoxib, meloxicam, diclofenac, ibuprofen, and naproxen on COX-2 versus COX-1 in healthy volunteers. J Clin Pharmacol 2000; 40: 1109-20.
25. Garcia Rodriguez LA, Varas C, Patrono C. Differential effects of aspirin and non-aspirin nonsteroidal antiinflammatory drugs in the primary prevention of myocardial infarction in postmenopausal women. Epidemiology 2000; 11: 382-7.
26. Ray WA, Stein CM, Hall K, Daugherty JR, Griffin MR. Non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease: an observational cohort study. Lancet 2002; 359: 118-23.
27. Farkouh ME, Kirshner H, Harrington RA et al. Comparison of lumiracoxibwith naproxenand ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomised controlled trial. Lancet 2004; 364: 675-85.
28. Konstam MA, Weir MR, Reicin AS et al. Cardiovascular thrombotic events in controlled, clinical trials of rofecoxib. Circulation 2001; 104: 2280-8.
29. Reicin AS, Shapiro D, Sperling RS, Barr E, Yu Q. Comparison of cardiovascular thrombotic events in patients with osteoarthritis treated with rofecoxib versus nonselective nonsteroidal anti-inflammatory drugs (ibuprofen, diclofenac, and nabumetone). Am J Cardiol 2002; 89: 204-09.
30. Mamdani M, Rochon P, Juurlink DN et al. Effect of selective cyclooxygenase 2 inhibitors and naproxen on short-term risk of acute myocardial infarction in the elderly. Arch Intern Med 2003; 163: 481-6.
31. Baron JA, Cole BF, Sandier RS et al. A randomized trial of aspirin to prevent colorectal adenomas. N Engl J Med 2003; 348: 891-9.
32. Juni P, Nartey L, Reichenbach S, Sterchi R, Dieppe PA, Egger M. Risk of cardiovascular events and rofecoxib: cumulative metanalysis. Lancet 2004; 364: 2021-9.
33. Solomon DH, Schneeweiss S, Glynn RJ et al. Relationship between selective cyclooxygenase-2 inhibitors and acute myocardial infarction in older adults. Circulation 2004; 109: 2068-73.
34. Ott E, Nussmeier NA, Duke PC et al. Efficacy and safety of the cyclooxygenase-2 inhibitors parecoxib and valdecoxib in patients undergoing coronary artery bypass surgery. J Thorac Cardiovasc Surg 2003; 125: 1481-92.
35. Hughes S: Coxibs: where do we go from here? http://www.theheart.org.
36. FitzGerald GA. COX-2 and beyond: approaches to prostaglandin inhibition in human disease. Nat Rev Drug Discov 2003; 2: 879-90.
37. Day R, Morrison S, Luza A et al. A randomized trial of the efficacy and tolerability of the COX-2 inhibitor rofecoxib. Arch Intern Med 2000; 160: 1781-7.
38. Cannon GW, Caldwell JR, Holt P et al. Rofecoxib, a specific inhibitor of cyclooxygenase 2, with clinical efficacy comparable with that of diclofenac sodium: results of a one-year, randomized, clinical trial in patients with osteoarthritis of the knee and hip. Arthritis Rheum 2000; 43: 978-87.
39. Ehrich EW, Schnitzer TJ, McIlwain H et al. Effect of specific COX-2 inhibition in osteoarthritis of the knee: a 6 week double blind, placebo controlled pilot study of rofecoxib. J Rheumatol 1999; 26: 2438-47.
40. Simon LS, Weaver AL, Graham DY et al. Anti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis: a randomized controlled trial. JAMA 1999; 282: 1921-8.
41. Lenzer J. US government agency to investigate FDA over rofecoxib. Br Med J 2004; 329: 935.
42. Lenzer J. FDA to review risks of antidepressants in adults. Br Med J 2004; 329: 816.
43. Farkouh ME, Kirshner H, Harrington RA et al. Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications: randomised controlled trial. Lancet 2004; 364: 665-74.
44. Davies NM, Jamali F. COX-2 selective inhibitors cardiac toxicity: getting to the heart of the matter. J Pharm Pharmaceut Sci 2004; 7: 332-6.
45. Okie S. Raisingthe safety bar-the FDA'scoxib meeting. N Engl J Med 2005; 352: 1283-5.